ZymoGenetics Acquisition Highlights Competitive Hepatitis C Treatment Race

Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.

Read more »

Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results

Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.

Read more »

Pressure BioSciences Aims for Improved Sample Preparation

Pressure BioSciences seeks to improve sample yield with its novel technology platform, known as pressure cycling technology (PCT).

Read more »

The Universal Vaccines of Inovio Biomedical

Inovio is developing a universal flu vaccine engineered to prevent several strains of influenza at once.

Read more »

Inovio Biomedical (AMEX: INO): A DNA Vaccine Delivery Innovator

Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.

Read more »

Human Genome’s Lupus Drug Surprises Analysts

Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial.

Read more »

Foresight’s Conjunctivitis Solution Beats Competitors In Study

FST-100 performed significantly better than other treatments for adenoviral conjunctivitis, including the current experimental “gold standard” topical cidofovir.

Read more »

[Video Profile] Inovio Biomedical Corporation

Solid tumors represent 85 percent of all cancers, creating a huge clinical need for localized, site-specific cancer treatment. Inovio Medical Corporation of San Diego is developing DNA-based vaccines that harness the body’s immune system to prevent and treat chronic diseases such as cancer and HIV.

Read more »